The Role of Regorafenib in Colorectal Cancer
S. Gail Eckhardt, MD, discusses the role of regorafenib in colorectal cancer.
S. Gail Eckhardt, MD, professor and head of the Division of Medical Oncology at the University of Colorado Denver and Health Sciences Center, discusses the role of regorafenib in colorectal cancer.
Clinical Pearls
- Regorafenib is a great option for community physicians who do not have access to clinical trials
- The approval of regorafenib gives physicians a level of activity to improve upon but is only an incremental improvement for patients
Retrospective Data Demonstrates Efficacy of Regorafenib in mCRC
April 16th 2024During a Case-Based Roundtable® event, Madappa Kundranda, MD, PhD, discussed recent retrospective studies that compared outcomes between the available treatment options in patients with relapsed/refractory advanced colorectal cancer in the first article of a 2-part series.
Read More
Acalabrutinib/Obinutuzumab Shows Improved PFS in Treatment-Naive CLL
April 10th 2024In an interview with Targeted Oncology, Jeff Sharman, MD, discussed the results of the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab at 74.5 months of follow-up among patients with chronic lymphocytic leukemia.
Read More
